Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: A phase II, randomized, double-blind, placebo-controlled pilot trial

Arthritis and Rheumatology

Volumn 67, Issue 11, 2015, Pages 2828-2836

  Van Vollenhoven, R F ^a   Wax, S ^b   Li, Y ^b   Tak, P P ^c,d,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b EMD SERONO INC   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATACICEPT; BIOLOGICAL MARKER; CORTICOSTEROID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHOTREXATE; PLACEBO; RITUXIMAB; ANTIRHEUMATIC AGENT; HYBRID PROTEIN; TACI RECEPTOR-IGG FC FRAGMENT FUSION PROTEIN;

ADULT; ALLERGIC REACTION; ARTICLE; BRAIN ARTERY ANEURYSM; CONJUNCTIVITIS; CONNECTIVE TISSUE DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; ERYTHEMA; EYE DISEASE; FEMALE; GASTRITIS; GASTROINTESTINAL DISEASE; HORDEOLUM; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOLOGY; INFECTION; INFLUENZA; INJECTION SITE REACTION; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; SKIN DISEASE; SUBCUTANEOUS TISSUE D; SWELLING; TRANSIENT ISCHEMIC ATTACK; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASCULAR DISEASE; AGED; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RITUXIMAB; TREATMENT OUTCOME;

EID: 84946082073     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39262     Document Type: Article

References (24)

1. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
2. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
3. Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, et al., Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 2012; 71: 351-7.
4. Bugatti S, Codullo V, Caporali R, Montecucco C., B cells in rheumatoid arthritis. Autoimmun Rev 2007; 7: 137-42.
5. Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, et al., Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010; 62: 1273-9.
6. Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, et al., The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012; 14: R95.
7. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP., Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008; 67: 917-25.
8. Dorner T, Kinnman N, Tak PP., Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 2010; 125: 464-75.
9. Cheema GS, Roschke V, Hilbert DM, Stohl W., Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-9.
10. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, et al., Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003; 48: 982-92.
11. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC., Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006; 54: 723-32.
12. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, et al., TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15: 289-302.
13. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al, and the Merck Serono and ZymoGenetics Atacicept Study Group. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4142-50.
14. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al., Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007; 66: 228-34.
15. Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP., Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011; 63: 1793-803.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
17. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
18. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al., American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
19. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, et al., Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008; 58: 61-72.
20. Van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J., Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011; 63: 1782-92.
21. Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al., Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68: 1156-64.
22. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G, et al., Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 2010; 49: 1683-93.
23. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al., Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) [published erratum appears in Ann Rheum Dis. 2011;70:1519]. Ann Rheum Dis 2010; 69: 1629-35.
24. Seyler TM, Park YW, Takemura S, Bram RJ, Kurtin PJ, Goronzy JJ, et al., BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005; 115: 3083-92.